Celldex Therapeutics Inc. (CLDX): Price and Financial Metrics

CLDX POWR Grades

• CLDX scores best on the Quality dimension, with a Quality rank ahead of 26.61% of US stocks.
• The strongest trend for CLDX is in Momentum, which has been heading down over the past 179 days.
• CLDX's current lowest rank is in the Sentiment metric (where it is better than 9.27% of US stocks).

CLDX Stock Summary

• Celldex Therapeutics Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 7.06% of US listed stocks.
• With a price/sales ratio of 358.22, Celldex Therapeutics Inc has a higher such ratio than 98.96% of stocks in our set.
• As for revenue growth, note that CLDX's revenue has grown -37.3% over the past 12 months; that beats the revenue growth of only 4.58% of US companies in our set.
• If you're looking for stocks that are quantitatively similar to Celldex Therapeutics Inc, a group of peers worth examining would be FULC, SURF, FUSN, MRUS, and MIRM.
• CLDX's SEC filings can be seen here. And to visit Celldex Therapeutics Inc's official web site, go to www.celldex.com.

CLDX Valuation Summary

• CLDX's price/earnings ratio is -37.1; this is 201.64% lower than that of the median Healthcare stock.
• Over the past 243 months, CLDX's EV/EBIT ratio has gone down 30.5.
• Over the past 243 months, CLDX's price/earnings ratio has gone down 30.2.

Below are key valuation metrics over time for CLDX.

CLDX Growth Metrics

Its 5 year cash and equivalents growth rate is now at -63.94%.
• Its 2 year cash and equivalents growth rate is now at -42.94%.
• The 3 year revenue growth rate now stands at 9.45%.

CLDX's revenue has moved down $1,647,000 over the prior 70 months.

The table below shows CLDX's growth in key financial areas (numbers in millions of US dollars).

Date	Revenue	Operating Cash Flow	Net Income to Common Stock
2021-12-31	4.651	-60.909	-70.511
2021-09-30	8.103	-51.597	-72.263
2021-06-30	8.618	-47.086	-66.035
2021-03-31	5.374	-46.378	-63.693
2020-12-31	7.418	-40.404	-59.78
2020-09-30	4.519	-46.193	-48.327

CLDX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.

• CLDX has a Quality Grade of D, ranking ahead of 19.92% of graded US stocks.
• CLDX's asset turnover comes in at 0.038 -- ranking 340th of 682 Pharmaceutical Products stocks.
• CALA, CYRX, and BDSI are the stocks whose asset turnover ratios are most correlated with CLDX.

The table below shows CLDX's key quality metrics over time.